Literature DB >> 28749770

In Silico Prediction of Antibiotic Resistance in Mycobacterium ulcerans Agy99 through Whole Genome Sequence Analysis.

Sushim Kumar Gupta1, Michel Drancourt1, Jean-Marc Rolain1.   

Abstract

Buruli ulcer is an emerging infectious disease caused by Mycobacterium ulcerans that has been reported from 33 countries. Antimicrobial agents either alone or in combination with surgery have been proved to be clinically relevant and therapeutic strategies have been deduced mainly from the empirical experience. The genome sequences of M. ulcerans strain AGY99, M. ulcerans ecovar liflandii, and three Mycobacterium marinum strains were analyzed to predict resistance in these bacteria. Fourteen putative antibiotic resistance genes from different antibiotics classes were predicted in M. ulcerans and mutation in katG (R431G) and pncA (T47A, V125I) genes were detected, that confer resistance to isoniazid and pyrazinamide, respectively. No mutations were detected in rpoB, gyrA, gyrB, rpsL, rrs, emb, ethA, 23S ribosomal RNA genes and promoter region of inhA and ahpC genes associated with resistance. Our results reemphasize the usefulness of in silico analysis for the prediction of antibiotic resistance in fastidious bacteria.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28749770      PMCID: PMC5590560          DOI: 10.4269/ajtmh.16-0478

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  39 in total

1.  A genotypic approach for detection, identification, and characterization of drug resistance in Mycobacterium ulcerans in clinical samples and isolates from Ghana.

Authors:  Marcus Beissner; Nana-Yaa Awua-Boateng; William Thompson; Willemien A Nienhuis; Erasmus Klutse; Pius Agbenorku; Joerg Nitschke; Karl-Heinz Herbinger; Vera Siegmund; Erna Fleischmann; Ohene Adjei; Bernhard Fleischer; Tjip S van der Werf; Thomas Loscher; Gisela Bretzel
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

2.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods.

Authors:  Koichiro Tamura; Daniel Peterson; Nicholas Peterson; Glen Stecher; Masatoshi Nei; Sudhir Kumar
Journal:  Mol Biol Evol       Date:  2011-05-04       Impact factor: 16.240

3.  [Buruli ulcer: hypothetical modes of transmission of Mycobacterium ulcerans].

Authors:  François Rodhain
Journal:  Bull Acad Natl Med       Date:  2012-03       Impact factor: 0.144

4.  The twin-arginine translocation pathway of Mycobacterium smegmatis is functional and required for the export of mycobacterial beta-lactamases.

Authors:  Justin A McDonough; Kari E Hacker; Anthony R Flores; Martin S Pavelka; Miriam Braunstein
Journal:  J Bacteriol       Date:  2005-11       Impact factor: 3.490

Review 5.  Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.

Authors:  Caroline Demangel; Timothy P Stinear; Stewart T Cole
Journal:  Nat Rev Microbiol       Date:  2009-01       Impact factor: 60.633

6.  Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice.

Authors:  A Bentoucha; J Robert; H Dega; N Lounis; V Jarlier; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

7.  Mutations found in the pncA gene of Mycobacterium tuberculosis in clinical pyrazinamide-resistant isolates from a local region of China.

Authors:  H Zhang; L-J Bi; C-Y Li; Z-G Sun; J-Y Deng; Xian-En Zhang
Journal:  J Int Med Res       Date:  2009 Sep-Oct       Impact factor: 1.671

Review 8.  Drug delivery systems for potential treatment of intracellular bacterial infections.

Authors:  Edurne Imbuluzqueta; Carlos Gamazo; Javier Ariza; Maria J Blanco-Prieto
Journal:  Front Biosci (Landmark Ed)       Date:  2010-01-01

9.  Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.

Authors:  Richard O Phillips; Fred S Sarfo; Mohammed K Abass; Justice Abotsi; Tuah Wilson; Mark Forson; Yaw A Amoako; William Thompson; Kingsley Asiedu; Mark Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

10.  Comparison of two assays for molecular determination of rifampin resistance in clinical samples from patients with Buruli ulcer disease.

Authors:  Moritz Jansson; Marcus Beissner; Richard Odame Phillips; Kossi Badziklou; Ebekalisai Piten; Issaka Maman; Fred Stephen Sarfo; Kristina Lydia Huber; Agata Rhomberg; Dominik Symank; Magdalena Wagner; Franz Wiedemann; Jörg Nitschke; Abiba Banla Kere; Karl-Heinz Herbinger; Ohene Adjei; Thomas Löscher; Gisela Bretzel
Journal:  J Clin Microbiol       Date:  2014-01-29       Impact factor: 5.948

View more
  2 in total

1.  Identification and Characterization of Mycobacterial Species Using Whole-Genome Sequences.

Authors:  Marco A Riojas; Andrew M Frank; Samuel R Greenfield; Stephen P King; Conor J Meehan; Michael Strong; Alice R Wattam; Manzour Hernando Hazbón
Journal:  Methods Mol Biol       Date:  2021

2.  Antimicrobial activity of Mycobacteriophage D29 Lysin B during Mycobacterium ulcerans infection.

Authors:  Alexandra G Fraga; Gabriela Trigo; Ramya K Murthy; Shamim Akhtar; Madhavi Hebbur; Ana Rita Pacheco; Juan Dominguez; Rita Silva-Gomes; Carine M Gonçalves; Hugo Oliveira; António G Castro; Umender Sharma; Joana Azeredo; Jorge Pedrosa
Journal:  PLoS Negl Trop Dis       Date:  2019-08-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.